Inozyme Pharma (NASDAQ:INZY) Downgraded to “Hold” Rating by Wedbush
Wedbush cut shares of Inozyme Pharma (NASDAQ:INZY – Free Report) from a strong-buy rating to a hold rating in a research note released on Friday,Zacks.com reports. Wedbush also issued estimates for Inozyme Pharma’s Q2 2025 earnings at ($0.34) EPS, FY2025 earnings at ($1.23) EPS, Q1 2026 earnings at ($0.25) EPS, Q2 2026 earnings at ($0.26) […]
Wedbush cut shares of Inozyme Pharma (NASDAQ:INZY – Free Report) from a strong-buy rating to a hold rating in a research note released on Friday,Zacks.com reports. Wedbush also issued estimates for Inozyme Pharma’s Q2 2025 earnings at ($0.34) EPS, FY2025 earnings at ($1.23) EPS, Q1 2026 earnings at ($0.25) EPS, Q2 2026 earnings at ($0.26) […]
-logo-1200x675.png?v=20240521153233&w=240&h=240&zc=2){kind=logo}
